AMENDED AND RESTATED COMMERCIAL MANUFACTURING SERVICES AND SUPPLY AGREEMENTCommercial Manufacturing Services and Supply Agreement • March 13th, 2024 • Liquidia Corp • Pharmaceutical preparations • New York
This Amended and Restated Commercial Manufacturing Services and Supply Agreement (the “Agreement”) is made and entered into as of July 13, 2023 (“Effective Date”), by and between Liquidia Technologies, Inc., with a principal place of business at 419 Davis Drive, Suite 100, Morrisville NC 27560 (“Customer”), and Lonza Tampa LLC f/k/a Xcelience, LLC, with principal place of business at 5415 West Laurel Street, Tampa, Florida 33607, USA (“Lonza”). Each of Lonza and Customer may be referred to herein individually as a “Party,” and Lonza and Customer may be referred to collectively as the “Parties.”
PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT UNDER RULE 24B-2 OF THE SECURITIES EXCHANGE ACT; [***] DENOTES OMISSIONS. COMMERCIAL...Commercial Manufacturing Services and Supply Agreement • May 5th, 2020
This Commercial Manufacturing Services and Supply Agreement (the “Agreement”) is made and entered into as of March 3, 2016 (“Effective Date”), by and between Lipocine Inc., with offices at 675 Arapeen Drive, Suite 202, Salt Lake City, UT 84108 (“Customer”), and M.W. Encap Ltd., together with its Affiliates, with offices at Units 4, 5 & 6, Oakbank Park, Livingston, West Lothian, EH53 0TH (“Encap”). Each of Encap and Customer may be referred to individually as a “Party,” and Encap and Customer may be referred to collectively as the “Parties.”
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED 2 of 17 • "Facility" means Lonza's...Commercial Manufacturing Services and Supply Agreement • August 8th, 2024 • Xeris Biopharma Holdings, Inc. • Pharmaceutical preparations • New York
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED 2 Copy to: [***] Copy to: [***]...Commercial Manufacturing Services and Supply Agreement • August 8th, 2024 • Xeris Biopharma Holdings, Inc. • Pharmaceutical preparations
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS OF THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. Amendment #01 to the COMMERCIAL...Commercial Manufacturing Services and Supply Agreement • November 10th, 2021 • Lipocine Inc. • Pharmaceutical preparations
Each of Encap and Customer may be referred to herein individually as a “Party,” and Encap and Customer may be referred to collectively as the “Parties.” Capitalized terms used herein and not defined will have the meanings ascribed to them in the Agreement.
COMMERCIAL MANUFACTURING SERVICES AND SUPPLY AGREEMENTCommercial Manufacturing Services and Supply Agreement • August 4th, 2020 • Deciphera Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
This Commercial Manufacturing Services and Supply Agreement (the “Agreement”) is made and entered into as of April 3rd, 2019 (“Effective Date”), by and between Deciphera Pharmaceuticals, LLC, having an address at 500 Totten Pond Road, 6th Floor, Waltham, Massachusetts 02451 (“Customer”), and [***] (“Lonza”). Each of Lonza and Customer may be referred to individually as a “Party,” and Lonza and Customer may be referred to collectively as the “Parties.”
